Literature DB >> 16959024

Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug?

N Maugeri1, G Giordano, M P Petrilli, V Fraticelli, G de Gaetano, C Cerletti, S Storti, M B Donati.   

Abstract

BACKGROUND: Polymorphonuclear leukocytes (PMN) from healthy subjects can produce and store tissue factor (TF), which is expressed on PMN surface upon in vitro stimulation with P-selectin.
RESULTS: We report here that platelets and PMN from 12 patients with myeloproliferative disorders (MPD) (six with polycythemia vera, six with essential thrombocythemia) show up regulation of P-selectin and TF, respectively, in the absence of any in vitro challenge. The number of circulating mixed platelet-PMN aggregates was also increased. PMN TF expression as well as mixed platelet-PMN aggregates, but not platelet P-selectin, were significantly reduced in six MPD patients after treatment with hydroxyurea (HU). In vitro studies performed on PMN separated from healthy donors confirmed HU effects (0-1400 microm). HU prevented both P-selectin-induced TF expression and mixed cell aggregate formation. The inhibitory effect of HU was specific for P-selectin-induced PMN activation, as it did not affect formyl-methionyl-leucyl-phenylalanine-induced PMN TF expression.
CONCLUSIONS: In MPD patients, platelet P-selectin-mediated TF expression on circulating PMN may play a role in thrombus formation and represents a novel target for the antithrombotic activity of HU.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16959024     DOI: 10.1111/j.1538-7836.2006.02194.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  20 in total

Review 1.  Translational mini-review series on immunology of vascular disease: mechanisms of vascular inflammation and remodelling in systemic vasculitis.

Authors:  N Maugeri; P Rovere-Querini; M Baldini; M G Sabbadini; A A Manfredi
Journal:  Clin Exp Immunol       Date:  2009-03-20       Impact factor: 4.330

Review 2.  Blood cell activation in myeloproliferative neoplasms.

Authors:  Francisco Cervantes; Eduardo Arellano-Rodrigo; Alberto Alvarez-Larrán
Journal:  Haematologica       Date:  2009-11       Impact factor: 9.941

3.  Multiple electrode aggregometry and thromboelastography in thrombocytopenic patients with haematological malignancies.

Authors:  Elin N Opheim; Torunn O Apelseth; Simon J Stanworth; Geir E Eide; Tor Hervig
Journal:  Blood Transfus       Date:  2018-12-13       Impact factor: 3.443

4.  Myeloproliferative Neoplasms, an Acquired Thrombophilic State: JAK2 and Beyond.

Authors:  Hara Prasad Pati; Prashant Sharma
Journal:  Indian J Hematol Blood Transfus       Date:  2016-06-17       Impact factor: 0.900

5.  Clinical, laboratory, and genetic risk factors for thrombosis in sickle cell disease.

Authors:  Andrew Srisuwananukorn; Rasha Raslan; Xu Zhang; Binal N Shah; Jin Han; Michel Gowhari; Robert E Molokie; Victor R Gordeuk; Santosh L Saraf
Journal:  Blood Adv       Date:  2020-05-12

Review 6.  Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2V617F mutations and laboratory findings: a meta-analysis.

Authors:  N Saki; R Shirzad; F Rahim; A Saki Malehi
Journal:  Clin Transl Oncol       Date:  2017-02-15       Impact factor: 3.405

7.  Hydroxyurea with AKT2 inhibition decreases vaso-occlusive events in sickle cell disease mice.

Authors:  Andrew Barazia; Jing Li; Kyungho Kim; Namrata Shabrani; Jaehyung Cho
Journal:  Blood       Date:  2015-08-11       Impact factor: 22.113

Review 8.  Are MPNs vascular diseases?

Authors:  Guido Finazzi; Valerio De Stefano; Tiziano Barbui
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

9.  Impaired apoptosis of megakaryocytes and bone marrow mononuclear cells in essential thrombocythemia: correlation with JAK2V617F mutational status and cytoreductive therapy.

Authors:  Jacek Treliński; Krzysztof Chojnowski; Barbara Cebula-Obrzut; Piotr Smolewski
Journal:  Med Oncol       Date:  2012-03-15       Impact factor: 3.064

10.  Platelet - leukocyte interactions: multiple links between inflammation, blood coagulation and vascular risk.

Authors:  Chiara Cerletti; Giovanni de Gaetano; Roberto Lorenzet
Journal:  Mediterr J Hematol Infect Dis       Date:  2010-08-13       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.